5-MeO-DiBF

5-MeO-DiBF
Clinical data
Routes of
administration		?
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • US: ?
Identifiers
  • N-[2-(5-Methoxy-1-benzofuran-3-yl)ethyl]-N-(propan-2-yl)propan-2-amine
CAS Number
  • none
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H25NO2
Molar mass275.392 g·mol−1
3D model (JSmol)
  • COC1=CC=C(OC=C2CCN(C(C)C)C(C)C)C2=C1
  • InChI=1S/C17H25NO2/c1-12(2)18(13(3)4)9-8-14-11-20-17-7-6-15(19-5)10-16(14)17/h6-7,10-13H,8-9H2,1-5H3
  • Key:NBFMSQBTYHYVKP-UHFFFAOYSA-N

5-MeO-DiBF is a psychedelic[1] that has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia.[2] It is thought to act as an agonist for the 5-HT1A and 5-HT2 family of serotonin receptors. It is related in structure to the psychedelic tryptamine derivative 5-MeO-DiPT, but with the indole nitrogen replaced by oxygen, making 5-MeO-DiBF a benzofuran derivative. It is several times less potent as a serotonin agonist than 5-MeO-DiPT and with relatively more activity at 5-HT1A, but still shows strongest effects at the 5-HT2 family of receptors.[3][4]

5-MeO-DiBF is not controlled under the 1971 Convention on Psychotropic Substances, so thus it has a legal grey area in many countries, but it's possible it could be illegal under so-called analogue acts if sold for human consumption.

See also

References

  1. ^ Casale JF, Hays PA. "The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog" (PDF). Microgram Journal. 9 (1): 39–45.
  2. ^ "Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). European Monitoring Center for Drugs and Drug Addiction.
  3. ^ Tomaszewski Z, Johnson MP, Huang X, Nichols DE (May 1992). "Benzofuran bioisosteres of hallucinogenic tryptamines". Journal of Medicinal Chemistry. 35 (11): 2061–4. doi:10.1021/jm00089a017. PMID 1534585.
  4. ^ McKenna DJ, Repke DB, Lo L, Peroutka SJ (March 1990). "Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes". Neuropharmacology. 29 (3): 193–8. doi:10.1016/0028-3908(90)90001-8. PMID 2139186. S2CID 24188017.


Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.